Cargando…

Inter-jurisdictional cooperation on pharmaceutical product listing agreements: views from Canadian provinces

BACKGROUND: Confidential product listing agreements (PLAs) negotiated between pharmaceutical manufacturers and individual health care payers may contribute to unwanted price disparities, high administrative costs, and unequal bargaining power within and across jurisdictions. In the context of Canada...

Descripción completa

Detalles Bibliográficos
Autores principales: Morgan, Steven G, Thomson, Paige A, Daw, Jamie R, Friesen, Melissa K
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2013
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3563436/
https://www.ncbi.nlm.nih.gov/pubmed/23363626
http://dx.doi.org/10.1186/1472-6963-13-34
_version_ 1782258182882590720
author Morgan, Steven G
Thomson, Paige A
Daw, Jamie R
Friesen, Melissa K
author_facet Morgan, Steven G
Thomson, Paige A
Daw, Jamie R
Friesen, Melissa K
author_sort Morgan, Steven G
collection PubMed
description BACKGROUND: Confidential product listing agreements (PLAs) negotiated between pharmaceutical manufacturers and individual health care payers may contribute to unwanted price disparities, high administrative costs, and unequal bargaining power within and across jurisdictions. In the context of Canada’s decentralized health system, we aimed to document provincial policy makers’ perceptions about collaborative PLA negotiations. METHODS: We conducted semi-structured telephone interviews with a senior policy maker from nine of the ten Canadian provinces. We conducted a thematic analysis of interview transcripts to identify benefits, drawbacks, and barriers to routine collaboration on PLA negotiations. RESULTS: Canadian policy makers expressed support for joint negotiations of PLAs in principle, citing benefits of increased bargaining power and reduced inter-jurisdictional inequities in drug prices and formulary listings. However, established policy institutions and the politics of individual jurisdictional authority are formidable barriers to routine PLA collaboration. Achieving commitment to a joint process may be difficult to sustain among heterogeneous and autonomous partners. CONCLUSIONS: Though collaboration on PLA negotiation is an extension of collaboration on health technology assessment, it is a very significant next step that requires harmonization of the outcomes of decision-making processes. Views of policy makers in Canada suggest that sustaining routine collaborations on PLA negotiations may be difficult unless participating jurisdictions have similar policy institutions, capacities to implement coverage decisions, and local political priorities.
format Online
Article
Text
id pubmed-3563436
institution National Center for Biotechnology Information
language English
publishDate 2013
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-35634362013-02-08 Inter-jurisdictional cooperation on pharmaceutical product listing agreements: views from Canadian provinces Morgan, Steven G Thomson, Paige A Daw, Jamie R Friesen, Melissa K BMC Health Serv Res Research Article BACKGROUND: Confidential product listing agreements (PLAs) negotiated between pharmaceutical manufacturers and individual health care payers may contribute to unwanted price disparities, high administrative costs, and unequal bargaining power within and across jurisdictions. In the context of Canada’s decentralized health system, we aimed to document provincial policy makers’ perceptions about collaborative PLA negotiations. METHODS: We conducted semi-structured telephone interviews with a senior policy maker from nine of the ten Canadian provinces. We conducted a thematic analysis of interview transcripts to identify benefits, drawbacks, and barriers to routine collaboration on PLA negotiations. RESULTS: Canadian policy makers expressed support for joint negotiations of PLAs in principle, citing benefits of increased bargaining power and reduced inter-jurisdictional inequities in drug prices and formulary listings. However, established policy institutions and the politics of individual jurisdictional authority are formidable barriers to routine PLA collaboration. Achieving commitment to a joint process may be difficult to sustain among heterogeneous and autonomous partners. CONCLUSIONS: Though collaboration on PLA negotiation is an extension of collaboration on health technology assessment, it is a very significant next step that requires harmonization of the outcomes of decision-making processes. Views of policy makers in Canada suggest that sustaining routine collaborations on PLA negotiations may be difficult unless participating jurisdictions have similar policy institutions, capacities to implement coverage decisions, and local political priorities. BioMed Central 2013-01-31 /pmc/articles/PMC3563436/ /pubmed/23363626 http://dx.doi.org/10.1186/1472-6963-13-34 Text en Copyright ©2013 Morgan et al.; licensee BioMed Central Ltd. http://creativecommons.org/licenses/by/2.0 This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Research Article
Morgan, Steven G
Thomson, Paige A
Daw, Jamie R
Friesen, Melissa K
Inter-jurisdictional cooperation on pharmaceutical product listing agreements: views from Canadian provinces
title Inter-jurisdictional cooperation on pharmaceutical product listing agreements: views from Canadian provinces
title_full Inter-jurisdictional cooperation on pharmaceutical product listing agreements: views from Canadian provinces
title_fullStr Inter-jurisdictional cooperation on pharmaceutical product listing agreements: views from Canadian provinces
title_full_unstemmed Inter-jurisdictional cooperation on pharmaceutical product listing agreements: views from Canadian provinces
title_short Inter-jurisdictional cooperation on pharmaceutical product listing agreements: views from Canadian provinces
title_sort inter-jurisdictional cooperation on pharmaceutical product listing agreements: views from canadian provinces
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3563436/
https://www.ncbi.nlm.nih.gov/pubmed/23363626
http://dx.doi.org/10.1186/1472-6963-13-34
work_keys_str_mv AT morgansteveng interjurisdictionalcooperationonpharmaceuticalproductlistingagreementsviewsfromcanadianprovinces
AT thomsonpaigea interjurisdictionalcooperationonpharmaceuticalproductlistingagreementsviewsfromcanadianprovinces
AT dawjamier interjurisdictionalcooperationonpharmaceuticalproductlistingagreementsviewsfromcanadianprovinces
AT friesenmelissak interjurisdictionalcooperationonpharmaceuticalproductlistingagreementsviewsfromcanadianprovinces